Reconciling the Paradox of Value-Based Drug Pricing

This article examines the paradox of value-based drug pricing, wherein lifesaving pharmaceuticals are increasingly priced based on perceived therapeutic value without regard to the development or production costs, with results that most observers would not recognize as offering value. Although this approach appears to promise to reward innovation and align incentives, it often results in unsustainable costs for consumers, health systems, and the government - particularly in the United States, where drug prices are dramatically higher than in other wealthy nations. This article dissects different pricing rationales and illustrates how market failures and monopolies combine with inadequate government policy to distort value-based logic into an illogical outcome. The authors propose reforms that preserve incentives for innovation while promoting affordability, including competitive market mechanisms, regulatory oversight, and international market recognition. The goal is to align value, access, innovation, and sustainability in pharmaceutical pricing.